Human immunodeficiency virus type 1 Negative regulatory factor (Nef)

Human immunodeficiency virus type 1 Negative regulatory factor (Nef) is a 27-34 kDa myristoylated accessory protein essential for viral pathogenesis and the progression to AIDS (UniProt P03406). While Nef lacks enzymatic activity, it acts as a versatile adaptor protein that manipulates host cell membrane trafficking and signal transduction pathways (Basmaciogullari & Pizzato, 2014). Key functions include the downregulation of surface CD4 to prevent superinfection and the sequestration of MHC-I molecules to evade detection by cytotoxic T lymphocytes (Landi et al., 2011). Nef also enhances the infectivity of progeny virions and modulates T-cell activation to promote a cellular environment conducive to viral replication (PubMed: 22435402). Because individuals infected with Nef-deleted HIV strains typically show low viral loads and delayed disease progression, Nef is a high-priority target for therapeutic intervention (Deacon et al., 1995). Current drug development efforts focus on small-molecule inhibitors that disrupt Nef's interaction with host kinases like Hck and the inclusion of Nef-derived peptides in therapeutic vaccines (ClinicalTrials.gov: NCT00659282). These vaccines, such as Vacc-4x, aim to elicit robust cellular immune responses to clear infected cells (Rockstroh et al., 2019). However, the high genetic variability of the Nef gene presents a significant challenge for universal drug and vaccine design (PubMed: 11836374).

Other names

Nef proteinNegative factor3' ORF proteinp27HIV-1 Nef

Therapeutic vaccines utilize Nef antigens to induce Nef-specific cytotoxic T-lymphocyte responses (Rockstroh et al., 2019), while experimental small molecules like B9 inhibit Nef's ability to downregulate surface receptors or interact with host signaling proteins like Hck kinase (PubMed: 25762746).